178 related articles for article (PubMed ID: 16474164)
1. The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine.
Ambrose Z; Julias JG; Boyer PL; Kewalramani VN; Hughes SH
J Virol; 2006 Mar; 80(5):2578-81. PubMed ID: 16474164
[TBL] [Abstract][Full Text] [Related]
2. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
4. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
5. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.
Jonckheere H; Witvrouw M; De Clercq E; Anné J
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):249-53. PubMed ID: 9491915
[TBL] [Abstract][Full Text] [Related]
6. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
Auwerx J; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.
Tuaillon E; Gueudin M; Lemée V; Gueit I; Roques P; Corrigan GE; Plantier JC; Simon F; Braun J
J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1543-9. PubMed ID: 15577405
[TBL] [Abstract][Full Text] [Related]
9. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Ambrose Z; Herman BD; Sheen CW; Zelina S; Moore KL; Tachedjian G; Nissley DV; Sluis-Cremer N
J Virol; 2009 Apr; 83(8):3826-33. PubMed ID: 19193782
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
11. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
Balzarini J; Pelemans H; Esnouf R; De Clercq E
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):255-60. PubMed ID: 9491916
[TBL] [Abstract][Full Text] [Related]
12. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).
García Lerma J; Schinazi RF; Juodawlkis AS; Soriano V; Lin Y; Tatti K; Rimland D; Folks TM; Heneine W
Antimicrob Agents Chemother; 1999 Feb; 43(2):264-70. PubMed ID: 9925516
[TBL] [Abstract][Full Text] [Related]
13. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
14. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Harrigan PR; Salim M; Stammers DK; Wynhoven B; Brumme ZL; McKenna P; Larder B; Kemp SD
J Virol; 2002 Jul; 76(13):6836-40. PubMed ID: 12050397
[TBL] [Abstract][Full Text] [Related]
15. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors.
King RW; Klabe RM; Reid CD; Erickson-Viitanen SK
Antimicrob Agents Chemother; 2002 Jun; 46(6):1640-6. PubMed ID: 12019069
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
[TBL] [Abstract][Full Text] [Related]
17. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Varghese V; Mitsuya Y; Shahriar R; Bachmann MH; Fessel WJ; Kagan RM; Shafer RW
Antimicrob Agents Chemother; 2009 May; 53(5):2196-8. PubMed ID: 19223644
[TBL] [Abstract][Full Text] [Related]
19. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
[TBL] [Abstract][Full Text] [Related]
20. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
